The impact of hepatic steatosis on outcomes of colorectal cancer patients with liver metastases: A systematic review and meta-analysis

Shengjie Yang¹, Renze Peng¹ and Leiming Zhou*
Department of Gastroenterology, Changxing County People’s Hospital, Huzhou, China

Background: It is unclear how hepatic steatosis impacts patient prognosis in the case of colorectal cancer with liver metastases (CRLM). The purpose of this review was to assess the effect of hepatic steatosis on patient survival and disease-free survival (DFS) in the case of CRLM.

Methods: We examined the databases of PubMed, CENTRAL, Embase, Google Scholar, and ScienceDirect for studies reporting outcomes of CRLM patients with and without hepatic steatosis. We performed a random-effects meta-analysis using multivariable adjusted hazard ratios (HR).

Results: Nine studies reporting data of a total of 14,197 patients were included. All patients had undergone surgical intervention. Pooled analysis of seven studies indicated that hepatic steatosis had no statistically significant impact on patient survival in CRLM (HR: 0.92 95% CI: 0.82, 1.04, I² = 82%, p = 0.18). Specifically, we noted that there was a statistically significant improvement in cancer-specific survival amongst patients with hepatic steatosis (two studies; HR: 0.85 95% CI: 0.76, 0.95, I² = 41%, p = 0.005) while there was no difference in overall survival (five studies; HR: 0.97 95% CI: 0.83, 1.13, I² = 78%, p = 0.68). On meta-analysis of four studies, we noted that the presence of hepatic steatosis resulted in statistically significant reduced DFS in patients with CRLM (HR: 1.32 95% CI: 1.08, 1.62, I² = 67%, p = 0.007).

Conclusion: The presence of hepatic steatosis may not influence patient survival in CRLM. However, scarce data is suggestive of poor DFS in CRLM patients with hepatic steatosis. Further prospective studies taking into account different confounding variables are needed to better assess the effect of hepatic steatosis on outcomes of CRLM.

Systematic review registration: [https://www.crd.york.ac.uk/prospero/#searchadvanced], identifier [CRD42022320665].

KEYWORDS
colorectal cancer, liver metastasis, fatty liver, hepatic steatosis, mortality
Introduction

Colorectal cancer (CRC) is the second most common cancer in women and the third most common cancer amongst men worldwide (1). While the prevalence of this malignancy has been high in Western populations, recent data suggests that CRC is being increasingly diagnosed even in developing regions (2). The disease is known to be an age-associated malignancy with the median age of diagnosis being 67 years (3). Data from the United States reveals that of 140,000 patients diagnosed with CRC in 2018, approximately 60% of the patients were above the age of 65 years and these contributed to almost 70% of deaths during this period (4).

With improvements in tumor detection and therapeutic modalities, patient survival in CRC has improved over time (5). Nevertheless, colorectal liver metastases (CRLM) are still a major cause of mortality in these patients. Data suggests that more than half of the patients with CRC develop liver metastases during the illness and the median survival time is only 5–20 months in patients receiving no treatment for the metastatic disease (6, 7). Other than liver transplantation, surgical resection is the only curative treatment available for such patients which leads to a 5-year survival of up to 50% (8, 9). However, survival after hepatic resection depends on several factors like pre-existing hepatocellular damage, transfusion requirements, the size of the largest metastasis, and its distance to the resection margin (10). Recognition of such variables is important to characterize patients, develop a personalized management plan, and provide a realistic picture of survival and recurrence to CRLM patients.

One such important factor which has received limited attention in the prognosis of CRLM patients is hepatic steatosis. Also known as non-alcoholic fatty liver disease (NAFLD), hepatic steatosis is characterized by deposition of micro or macrovesicular lipid droplets in at least 5% of hepatocytes or more than 5% of liver weight without any signs of inflammation. While in most cases hepatic steatosis is the same as NAFLD, in some cases it may be attributable to alcohol as well (11). Irrespective of the etiology, in many patients, the disease gradually progresses to steatohepatitis and cirrhosis resulting in attenuated liver metabolic function and inflammation. Such deranged liver histology provides a fertile ground for seeding and colonization of CRC metastatic cells (12). To date, many studies have examined the effect of hepatic steatosis on outcomes of CRLM, however, with conflicting results. While some studies report no change in outcomes with hepatic steatosis (13, 14), others report poor patient survival and increased risk of recurrence (12, 15). Given the ambiguity in literature and the absence of a systematic review, the present study was designed to pool evidence on the effect of hepatic steatosis, irrespective of the etiology, on long-term outcomes of CRLM patients undergoing surgical intervention.

Materials and methods

Database search

The protocol of the review was registered on PROSPERO with registration no CRD42022320665. We looked into the databases of PubMed, CENTRAL, Embase, Google Scholar, and ScienceDirect for studies assessing the impact of hepatic steatosis on CRLM patients. This was done using the search terms “fatty liver,” “liver fat,” “hepatic steatosis,” “rectal cancer,” “colorectal cancer,” “colon cancer” and “metastasis.” The search strategy was common to all databases (Supplementary Table 1) and was performed by two of the study reviewers separately. The last date of the search was 28th March 2021. Once the initial search results were obtained, the results were exported and deduplicated. We then reviewed the unique results by reading the titles and abstracts to perform an initial screening. Only those studies which seemed to fulfill the eligibility criteria were downloaded for final screening. Inter-reviewer differences in the selection process were resolved in consultation with the third reviewer. We also undertook a hand-search of the reference list of the eligible studies to check for any missed relevant studies. The PRISMA guidelines were followed to report the review (16).

Inclusion criteria

We included the following studies: (1) Cohort and case-control studies performed on individuals with CRLM undergoing surgical resection. (2) Studies comparing outcomes of patients with and without hepatic steatosis irrespective of the etiology. (3) Outcomes of interest were patient survival [overall survival (OS) and cancer-specific survival (CSS)] and disease-free survival (DFS), (4) Studies reporting multivariable-adjusted effect size with 95% confidence intervals (CI). (5) Follow-up duration of more than 6 months.

We excluded: (1) Studies reporting on a general cohort of CRC patients. (2) Studies on patients without any surgical intervention. (3) Studies reporting only crude outcomes. (4) Studies reporting only immediate mortality rates (in-hospital, 30-day, 90-day). (5) Studies only on hepatic fibrosis or steatohepatitis. (6) Non-English language studies. (7) Studies with duplicate data. In case studies had partial overlap of data, the study with the largest sample size was to be included.

Data management and risk of bias

The following data was sourced from the studies: first author, publication year, type of the study, study location and database, inclusion criteria, diagnosis of hepatic steatosis, number of participants, demographic details, details of
neoadjuvant chemotherapy, largest metastasis, nodal invasion outcomes, and follow-up.

Risk of bias was examined using the Newcastle-Ottawa scale (NOS) (17). The scale assesses the studies for selection of study population, comparability, and outcomes. The maximum points in the scale are nine. A study with $\leq 6$, 7–8 and 9 points had high, moderate and low risk of bias respectively. Quality assessment was conducted by two reviewers with differences being resolved by the third reviewer.

**Statistical analysis**

Outcome data reported as adjusted hazard ratios (HR) were pooled in the meta-analysis software "Review Manager" [RevMan, version 5.3; Nordic Cochrane Centre (Cochrane Collaboration), Copenhagen, Denmark; 2014] to obtain pooled HR with 95% CI in a random-effects meta-analysis model. The $I^2$ scores were used to assess heterogeneity. $I^2 = 25–50\%$ meant low, 50–75\% meant medium, and more than 75\% meant substantial heterogeneity. We also conducted a leave-one-out sensitivity analysis to assess the effect of each study on the overall results. Due to limited number of studies (less than 10), funnel plots were not used to judge for publication bias.

**Results**

We retrieved 1,031 unique articles for review (Figure 1). After initial screening, 1,015 records were excluded. Of the 16 studies selected for full-text analysis, seven studies were excluded with reasons. A total of nine studies fulfilled the eligibility criteria and were included in this review (12–15, 18–22).

Baseline details of these studies are presented in Table 1. All were retrospective cohort studies published between 2013 and 2021. Two studies (14, 19) were multicentric reporting data from multiple countries across the world. One (12) was conducted on the Asian population while the rest were on Western populations. The study period was wide-ranging from 1987 to 2019. Hepatic steatosis was diagnosed histologically in all studies, except one (12) wherein radiological criteria were
| Study       | Location                  | Database                                | Period            | Patient population description                                                                 | Diagnosis of fatty liver | Group       | Sample size | Mean age  | Male gender (%) | BMI (kg/m²) | NC (%) | Largest metastasis > 5 cm (%) | Lymph node invasion | Follow-up |
|------------|---------------------------|-----------------------------------------|-------------------|-------------------------------------------------------------------------------------------------|--------------------------|-------------|-------------|-----------|-----------------|-------------|--------|-----------------------------|----------------------|------------|
| van Dijk (15) | Netherlands               | Maastricht University Medical Centre   | 2008–2013         | CRLM patients who underwent partial hepatectomy                                               | H                        | Fatty Liver Control | 135         | 64.8       | 64               | 27.1 ± 3.7 | 68     | 12                          | 64                    | Median    |
| Chen (12)   | China                     | Second Affiliated Hospital of Zhejiang University School of Medicine | 2012–2019         | CRLM patients who underwent resection of the primary site and hepatectomy/RFA with curative intention | R                        | Fatty Liver Control | 39          | NR         | NR               | NR          | 58.9   | 23.1                        | 71.8                  | Median    |
| Alabraba (22) | United Kingdom             | Nottingham University Hospitals        | 2004–2017         | CRLM patients who curative surgical resection                                                | H                        | Fatty Liver Control | 160         | NR         | NR               | NR          | NR     | NR                          | NR                    | Median    |
| Mahlmann (20) | Germany                    | Hannover Medical School                | 2000–2014         | CRLM patients who underwent liver resection                                                  | H                        | Fatty Liver Control | 277         | NR         | NR               | NR          | NR     | NR                          | NR                    | NR        |
| Ramos (21)  | Spain                     | Hospital Universitario de Bellvitge    | 1990–2014         | CRLM patients who underwent liver resection                                                  | H                        | Fatty Liver Control | 421         | 62.6       | 70.1             | NR          | 41.2   | NR                          | NR                    | Median    |
| Parkin (19) | Multicentric              | LiverMetSurvey                          | 1990–2011         | CRLM patients who underwent liver resection with pre-operative chemotherapy                 | H                        | Fatty Liver Control | 1675        | 62.7       | NR               | 100         | NR     | NR                          | NR                    | Median    |

(Continued)
TABLE 1 (Continued)

| Study | Location Database | Period | Patient population | Diagnosis Group of fatty liver | Sample size | Mean age | Male gender (%) | BMI (kg/m²) | Lymph node invasion >5 cm (%) | Largest metastasis >5 cm (%) |
|-------|--------------------|--------|--------------------|-------------------------------|-------------|----------|-----------------|------------|-------------------------------|-----------------------------|
| Viganò (13) | Switzerland | 1998–2011 | CRLM patients who underwent liver resection with pre-operative chemotherapy | H | 73 | NR | 250 | 71 | NR | 64.5 | NR | 58.9 | 35.9 | 50 | Median 36.9 months |
| Parkin (14) | Multicentric LiverMetSurvey | 1990–2011 | CRLM patients who underwent liver resection without pre-operative chemotherapy | H | 1793 | 3522 | 64.5 | 63.9 | 32.2 | 58.3 | NR | 0 | 0 | 30.8 | 59.7 | Median 20 months |
| Hamady (18) | United Kingdom | 1987–2010 | CRLM patients who underwent liver resection without pre-operative chemotherapy | H | 927 | 1788 | 68.9 | 61.3 | NR | 68.9 | NR | 54.4 | 30.1 | 71.2 | 39.9 | Median 34 months |

OS, overall survival; DFS, disease-free survival; CSS, cancer-specific survival; CI, confidence interval; CRLM, colorectal liver metastases; NC, neoadjuvant chemotherapy; H, histological; R, radiological.

used. A total of 14,197 patients were included in all nine studies. The mean age was > 60 years in most studies. The proportion of male patients ranged from 32.2 to 70.1%. Three studies (20–22) did not report data on the use of neoadjuvant chemotherapy. Only one study (15) reported data on body mass index (BMI) in the study and control groups. For the remaining studies, the percentage of patients receiving neoadjuvant chemotherapy ranged from 0 to 100%. The incidence of nodal invasion in the study cohorts ranged from 30 to 71.8%. The studies had a follow-up ranging from a median of 7–127 months. The results of individual studies and the adjusted covariates in the analysis are presented in Table 2.

Meta-analysis

Five studies reported data on OS while two presented data on CSS. Pooled analysis of all seven studies indicated that hepatic steatosis had no statistically significant impact on patient survival in CRLM (HR: 0.92 95% CI: 0.82, 1.04, I² = 82%, p = 0.18) (Figure 2). Individually, we noted that there was statistically significant improvement in CSS amongst patients with hepatic steatosis (HR: 0.85 95% CI: 0.76, 0.95, I² = 41%, p = 0.005) while there was no difference in OS (HR: 0.97 95% CI: 0.83, 1.13, I² = 78%, p = 0.68). On sensitivity analysis, there was no change in the significance of the results of patient survival on the exclusion of any study (Table 3).

Four studies reported data on DFS. On meta-analysis, we noted that the presence of hepatic steatosis resulted in statistically significant reduced DFS in patients with CRLM (HR: 1.32 95% CI: 1.08, 1.62, I² = 67%, p = 0.007) (Figure 3). On the sequential exclusion of one study at a time, the results were still statistically significant with the HR ranging from 1.28 to 1.50 (Table 3). However, on the exclusion of the study of Alabraba (22), the results demonstrated a tendency of reduced DFS with hepatic steatosis but with non-significant results. Risk of bias analysis is presented in Table 4. The NOS score of the studies was either 7 or 8 indicating moderate quality.

Discussion

NAFLD is one of the most common causes of chronic liver disease worldwide. NAFLD is characterized by the accumulation of excess fat in the liver that is not attributable to alcohol. Indeed, the increased prevalence of metabolic syndrome and obesity has expanded the presence of NAFLD (11). Global estimates indicate that around 25.24% of the world population suffers from the disease (23) with its spectrum including hepatic steatosis, hepatic steatohepatitis, and hepatic fibrosis/cirrhosis in advanced cases (24). Due to the complex nature of the disease, the relationship between NAFLD and
TABLE 2 Details of study results and covariates adjusted in the analysis.

| Study         | Outcomes [Hazard ratio (95% CI)] | Covariates adjusted                                      |
|---------------|----------------------------------|---------------------------------------------------------|
| van Dijk (15) | OS: 1.8 (1, 3) DFS: 1.8 (1, 3) | Sex, age, American Society of Anesthesiologists, comorbidity, neoadjuvant chemotherapy, radical resection, Fong score |
| Chen (12)     | DFS: 1.86 (1.23, 2.82)          | Tumor location, number of liver metastasis, preoperative chemotherapy, surgery type, KRAS mutation, BRAF mutation |
| Alabraba (22) | DFS: 1.285 (1.086–1.520)       | Synchronous/metachronous presentation, neoadjuvant chemotherapy, surgery type, tumor size, number of metastases, vascular invasion, perineural invasion, R0 resection margin |
| Mahlmann (20) | OS: 0.997 (0.987, 1.007)       | NR                                                      |
| Ramos (21)    | OS: 0.81 (0.63, 1.03)          | Age, portal vein embolization, major liver resection, perioperative transfusion |
| Parkin (19)   | CSS: 0.904 (0.796, 1.026)      | Node positive primary, number of hepatic metastases > 3, carcinoembryonic antigen level > 60 ng/mL, tumor diameter ≥ 5 cm, positive resection margin, extra-hepatic disease |
| Viganò (13)   | OS: 0.354 (0.183, 0.684)       | Number of metastases, “N” stage, tumor diameter, extra-hepatic disease, adjuvant chemotherapy, chemotherapy related-liver injuries, tumor regression grade, percentage of viable cells on histology, positive resection margin |
| Parkin (14)   | CSS: 0.806 (0.717, 0.905)      | Node positive primary, number of hepatic metastases > 3, carcinoembryonic antigen level > 60 ng/mL, tumor diameter ≥ 5 cm, positive resection margin, extra-hepatic disease |
| Hamady (18)   | OS: 1.08 (0.97, 1.21) DFS: 1.11 (1.01, 1.22) | Age, sex, lymph node status of the primary tumor, timing of liver metastases (synchronous versus metachronous), disease-free interval, presence of extrahepatic disease at time of diagnosis, largest hepatic metastasis diameter, number of liver metastases, lobar distribution (unilateral versus bilateral), carcinoembryonic antigen level, preoperative chemotherapy, resection margin status |

NR, not reported.

malignancies has been quite intriguing. In a recent meta-analysis, Liu et al. (25) have suggested that NAFLD is associated with a statistically significant increased risk of CRC, intrahepatic cholangiocarcinoma, extrahepatic cholangiocarcinoma, breast, gastric, pancreatic, prostate, and esophageal cancer. While the increased risk of CRC is postulated by this review, it is unclear if the disease impacts outcomes of CRC especially those with liver metastases.

The focus of our meta-analysis was to assess if the presence of hepatic steatosis, irrespective of its etiology, leads to poor patient survival and increased risk of recurrence in patients with CRLM. We specifically chose to assess this risk only with hepatic steatosis as it is the most common phenotype of NAFLD and only 10–30% of patients develop steatohepatitis and fibrosis (11). Commensurating with the prevalence, the majority of the studies in literature also reported data on hepatic steatosis rather than steatohepatitis or fibrosis. For the first meta-analysis, we noted that the presence of hepatic steatosis did not affect patient survival. On examination of individual study data, one can note that the study of Viganò (13) and
FIGURE 3
Meta-analysis of the impact of hepatic steatosis on DFS in CRLM.

TABLE 3 Results of sensitivity analysis.

| Excluded study | Hazard ratio |
|----------------|--------------|
| **Patient survival** | |
| Hamady (18) | 0.88 95% CI: 0.76, 1.03 I² = 84% p = 0.11 |
| Viganò (13) | 0.95 95% CI: 0.86, 1.05 I² = 79% p = 0.31 |
| Ramos (21) | 0.94 95% CI: 0.83, 1.06 I² = 84% p = 0.33 |
| Mahlmann (20) | 0.89 95% CI: 0.74, 1.07 I² = 82% p = 0.23 |
| van Dijk (15) | 0.91 95% CI: 0.81, 1.01 I² = 83% p = 0.09 |
| Parkin (14) | 0.96 95% CI: 0.85, 1.08 I² = 75% p = 0.49 |
| Parkin (19) | 0.93 95% CI: 0.80, 1.07 I² = 84% p = 0.28 |
| **Disease free survival** | |
| Hamady (18) | 1.50 95% CI: 1.15, 1.96 I² = 42% p = 0.003 |
| Alabraba (22) | 1.46 95% CI: 0.97, 2.20 I² = 75% p = 0.07 |
| Chen (12) | 1.22 95% CI: 1.03, 1.43 I² = 55% p = 0.02 |
| van Dijk (15) | 1.28 95% CI: 1.04, 1.57 I² = 72% p = 0.02 |

CI, confidence interval.

Parkin (14) reported a protective role of hepatic steatosis on patient survival while the others noted no effect on mortality rates. The contrasting result is difficult to explain because hepatic steatosis is a pathological condition that is associated with an increased risk of cancer and even CRLM recurrence (according to our results). One plausible reason could be the association of hepatic steatosis with obesity. Pathak et al. (26) have shown that BMI but not diabetes independently predicts the development of hepatic steatosis. Furthermore, there is evidence to suggest the occurrence of the “obesity paradox” wherein high BMI is associated with better survival in CRC patients (27). Considering the complex association between NAFLD, BMI, body composition, and patient survival it is possible that the improved survival with hepatic steatosis in these studies could have been due to the excessive influence of one factor over the other. The lack of such contrasting results in the remaining studies along with the stability of the outcome on sensitivity analysis lends support to the conclusion that hepatic steatosis may not influence patient survival in CRLM. Our results concur with other studies which could not be included in our meta-analysis. Pathak et al. (26) in their study of 102 patients undergoing hepatectomy for CRLM has shown no difference in mean survival in patients with and without hepatic steatosis (28.6 vs. 32.3 months). Zhao et al. (28) have also noted no impact of steatohepatitis on patient survival after CRLM. While our review was focused only on the long-term impact of hepatic steatosis, studies assessing short-term morbidity and mortality outcomes have produced conflicting results as well. Older studies (29, 30) have shown that the presence of hepatic steatosis increases the risk of early morbidity and mortality in patients undergoing liver resections, however, more recent data segregating steatosis from steatohepatitis shows no such effect (31, 32).

In the second meta-analysis of just four studies, we noted that the presence of hepatic steatosis significantly reduced DFS in CRLM patients. Individually, the results were consistent across the four included studies but the lower end of 95% CI was close to 1 in the majority of the studies (indicative of no difference). Thus, the results should be interpreted with caution and there is a need for further data to strengthen the credibility of the current evidence. However, in concurrence with our results, studies not included in the meta-analysis have also shown a similar impact of hepatic steatosis on DFS in CRLM. Molla et al. (33) in an analysis of 60 patients undergoing curative resection for CRLM noted an increased risk of recurrence in patients with NAFLD. Expanding further from hepatic steatosis to a more severe form of NAFLD, Kondo et al. (34) in a cohort of 953 CRC patients have shown that hepatic fibrosis significantly increases the risk of hepatic-specific recurrence. Similarly, Narayan et al. (35) assessing the influence of hepatic parenchymal disease (i.e., steatosis, hepatocyte ballooning, lobular inflammation, and fibrosis) on CRLM outcomes have also noted reduced DFS with liver disease.

The mechanism behind increased recurrence in CRLM has been attributed to the favorable microenvironment created by hepatic steatosis for tumor seeding. The pathophysiology of hepatic steatosis is modulated by several cytokines like transforming growth factor β, interleukins, and tumor necrosis factor-α which in turn also promote the development of liver metastases in CRC patients (36, 37). Dysregulated presence
of such cytokines causes a dual autocrine and paracrine effect resulting in an inflammatory milieu that creates a pre-metastatic niche for CRLM (38). Animal studies have also reported that the presence of steatosis significantly increases the risk of liver metastases (39). The suggested mechanism is that fatty acid transporter protein 1 transports lipolytic products into cancer cells and promotes tumor growth by mitochondrial oxidation (39). The presence of hepatic steatosis also leads to extracellular matrix remodeling and reorganization thereby creating a fibrotic niche for CRLM (40).

An important factor that can influence the risk of both steatosis and prognosis of patients with CRLM is neoadjuvant chemotherapy. Preoperative chemotherapy can improve disease control and convert initially unresectable malignancies for surgery in selected patients. In the case of resectable disease, the therapy can lower the burden of metastases and improve surgical outcomes (13). However, chemotherapy itself is associated with liver injuries ranging from sinusoidal obstruction syndrome lesion, nodular regenerative hyperplasia, steatosis, and steatohepatitis which in turn can potentially worsen surgical morbidity and mortality (20). However, liver injuries with chemotherapy are regimen-specific. Oxaliplatin-based regimens and irinotecan-based regimens are known to increase the risk of sinusoidal injury and steatohepatitis respectively, on the other hand, bevacizumab with FOLFOX reduces the risk of grade 2 or greater sinusoidal injury (41). Amongst the included studies, there was a large variation in the percentage of patients receiving neoadjuvant chemotherapy (0–100%) while two studies did not report data on the same. We were unable to differentiate between chemotherapy-induced steatosis and steatosis present before the development of CRLM. The wide variation and a limited number of studies also precluded a subgroup analysis based on preoperative chemotherapy.

Other limitations of our review need to be specified as well. Foremost, the limited number of studies and the retrospective nature of data is a significant drawback. Retrospective studies are inherently prone to selection bias. Furthermore, despite including nine studies in the review, not all studies reported data on patient survival and DFS which further decreased the statistical power of each analysis. Secondly, baseline details of study participants were either not available or varied across the included studies. Differences in important variables like tumor location, tumor size, nodal invasion, number and size of metastases, adjuvant therapies, etc., could have skewed the study results. An attempt was made to skirt this limitation by using only multivariable-adjusted data, however, the difference between the studies in the adjusted outcomes could not be negated. Thirdly, our meta-analysis could not differentiate between the different grades of hepatic steatosis due to a lack of adequate data from the included studies. Patients were grouped based on just presence and absence of hepatic steatosis. Also

| Study | Selection | Comparability | Outcome | Total |
|-------|-----------|---------------|---------|-------|
|       | Representativeness of the exposed cohort | Additional factor | Assessmnt of outcome | Outcome does not present at start |
| van Dijk (1) | + | + + + + + + + + | 0 | 8 |
| Chen (2) | + | + + + + + + + | 0 | 0 |
| Mahnmann (3) | + | + + + + + + | 0 | 7 |
| Ramos (4) | + | + + + + + + | 0 | 7 |
| Parkin (5) | + | + + + + + + + | 0 | 8 |
| Vignano (6) | + | + + + + + + + | 0 | 8 |
| Parkin (7) | + | + + + + + + + | 0 | 8 |
| Hamady (8) | + | + + + + + + + | 0 | 8 |
due to limited data on steatohepatitis and hepatic fibrosis in literature, our review only focused on hepatic steatosis. Lastly, hepatic steatosis could be either due to NAFLD or in some cases may be attributable to alcohol. The data of the included studies precluded any differentiation in outcomes based on the drivers of steatosis.

Our findings have clinical implications. Since initial limited data is indicative of poor DFS in patients with hepatic steatosis, we believe clinicians should include this point in patient–doctor interactions and aggressively monitor hepatic steatosis patients for recurrence. However, considering the scarce data the findings need to be concurred by additional studies. Also, future prospective studies with a large sample size are needed to better elucidate the impact of the entire spectrum of NAFLD on the prognosis of CRLM patients.

**Conclusion**

Our review which is the first to assess the impact of hepatic steatosis on outcomes of CRLM patients indicates that the presence of hepatic steatosis may not influence patient survival. However, scarce data is suggestive of poor DFS in CRLM patients with hepatic steatosis. Further prospective studies taking into account different confounding variables are needed to better assess the effect of hepatic steatosis on outcomes of CRLM.

**Data availability statement**

The original contributions presented in this study are included in the article/Supplementary material, further inquiries can be directed to the corresponding author/s.

**References**

1. Pérez-Escalante E, Caritho-Cortés R, Fernández-Martínez E, Ortiz MI, Muñoz-Pérez VM, Sánchez-Cruisistomo J, et al. Colorectal cancer: causes and evidence of chemopreventive treatments. *Curr Pharm Biotechnol*. (2018) 19:1135–55. doi: 10.2174/1389201020666181226112712

2. Brenner H, Chen C. The colorectal cancer epidemic: challenges and opportunities for primary, secondary and tertiary prevention. *Br J Cancer*. (2018) 119:785–92. doi: 10.1038/s41416-018-0264-X

3. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. *CA Cancer J Clin*. (2018) 68:394–424. doi: 10.3322/CACC.21492

4. Papamichael D, Hernandez P, Mistry R, Xenophontos E, Kakani C. Adjuvant chemotherapy in patients with colorectal cancer. Is there a role in the older adult? *Eur J Surg Oncol*. (2020) 46:363–8. doi: 10.1016/J.EJSO.2020.01.002

5. Iversen LH, Green A, Ingelholm P, Østerlind K, Gögenur I. Improved survival of colorectal cancer in Denmark during 2001–2012 – the efforts of several national initiatives. *Acta Oncol*. (2016) 55:10–23. doi: 10.3109/0284186X.2015.1131331

6. van Cutsem E, Nordlinger B, Cervantes A. Advanced colorectal cancer: ESMO clinical practice guidelines for treatment. *Ann Oncol Off J Eur Soc Med Oncol*. (2016) 27:201–21. doi: 10.1093/annonc/mdw631

7. Brenner H, Chen C. The colorectal cancer epidemic: challenges and opportunities for primary, secondary and tertiary prevention. *Br J Cancer*. (2018) 119:785–92. doi: 10.1038/s41416-018-0264-X

8. Brenner H, Chen C. The colorectal cancer epidemic: challenges and opportunities for primary, secondary and tertiary prevention. *Br J Cancer*. (2018) 119:785–92. doi: 10.1038/s41416-018-0264-X

9. Brenner H, Chen C. The colorectal cancer epidemic: challenges and opportunities for primary, secondary and tertiary prevention. *Br J Cancer*. (2018) 119:785–92. doi: 10.1038/s41416-018-0264-X

10. Brenner H, Chen C. The colorectal cancer epidemic: challenges and opportunities for primary, secondary and tertiary prevention. *Br J Cancer*. (2018) 119:785–92. doi: 10.1038/s41416-018-0264-X

**Author contributions**

SY and RP conceived and designed the study. SY, RP, and LZ collected the data and performed the analysis. LZ was involved in the writing of the manuscript and responsible for the integrity of the study. All authors have read and approved the final manuscript.

**Conflict of interest**

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

**Publisher’s note**

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

**Supplementary material**

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fmed.2022.938718/full#supplementary-material
11. Nassir F, Rector RS, Hammoud GM, Ibdah JA. Pathogenesis and prevention of hepatic steatosis. Gastroenterol Hepatol. (2015) 11:167.

12. Chen H, Dai S, Fang Y, Chen L, Jiang K, Wei Q, et al. Hepatic steatosis predicts higher incidence of recurrence following resection of colorectal liver metastasis patients. Front Oncol. (2011) 1:63943. doi: 10.3389/FONC.2011.63943

13. Viganó L, Capussotti L, De Rosa G, De Sausmarez WO, Mentha G, Rubbia-Brandt L. Liver resection for colorectal metastases after chemotherapy: impact of chemotherapeutic-related liver injuries, pathological tumor response, and micrometastases on long-term survival. Ann Surg. (2013) 258:731–42. doi: 10.1097/SLA.0b013e182a6183E

14. Parkin E, O’Reilly DA, Adam R, Kaiser GM, Laurent C, Elias D, et al. The effect of hepatic steatosis on survival following resection of colorectal liver metastases in patients without preoperative chemotherapy. HPB (Oxford). (2013) 15:463–72. doi: 10.1111/HBP.12007

15. van Dijk DP, Zhao J, Kemter K, Baracos VE, Dejong CHC, Rensen SS, et al. Ectopic fat in liver and skeletal muscle is associated with shorter overall survival in patients with colorectal liver metastases. J Cachexia Sarcopenia Muscle. (2012) 1:983–92. doi: 10.1002/JCSM.12723

16. Page MJ, McKenzie JE, Bossuyt PM, Bontour I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. Int J Surg. (2021) 88:105906. doi: 10.1016/j.ijsu.2021.105906

17. Wells G, Shea B, O’Connell D, Peterson J, Welch V, Losos M, et al. The Newcastle-Ottawa Scale (NOS) for Assessing the Quality of Nonrandomised Studies in Meta-Analyses. (2020). Available online at: http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp (accessed October 30, 2020).

18. Hamady ZZB, Rees M, Welsh FK, Tongood GJ, Prasad KR, John TK, et al. Fatty liver disease as a predictor of local recurrence following resection of colorectal liver metastases. Br J Surg. (2013) 100:980–9. doi: 10.1002/BJS.9057

19. Parkin E, O’Reilly DA, Adam R, Kaiser GM, Laurent C, Elias D, et al. Equivalent survival in patients with and without steatosis undergoing resection for colorectal liver metastases following pre-operative chemotherapy. Eur J Surg Oncol. (2014) 40:1436–44. doi: 10.1016/J.EJSO.2014.07.040

20. Mahlmann JC, Wirth TC, Hartleben B, Schrem H, Mahlmann JE, Kaltenborn A, et al. Chemotherapy and hepatic steatosis: impact on postoperative morbidity and survival after liver resection for colorectal liver metastases. J Clin Med. (2021) 31:198–205. doi: 10.1159/000510661

21. Ramos E, Torras J, Lladó L, Rafecas A, Serrano T, Lopez-Gordo S, et al. Impact of chemotherapy-related liver injuries, pathological tumor response, and micrometastases on long-term survival. Ann Surg Oncol. (2012) 19:4287–99. doi: 10.1245/BJCO.2012.11.002

22. Alabraba E, Ibrahim H, Olaru A, Cameron I, Gomez D, Group NHS. Retrospective cohort study of statin therapy effect on resected colorectal liver metastases. World J Gastrointest Surg. (2015) 7:38–44. doi: 10.4240/WJG.S.V.12.12.34

23. Younossi ZM, Koenig AB, Abdelatif D, Fazel Y, Henry L, Wymer M, et al. The spectrum of non-alcoholic fatty liver disease: a systematic review and meta-analysis. Gastroenterol Hepatol. (2016) 10:160. doi: 10.1002/CTM.2.160

24. Pathak S, Tang IMF, Terlizzi M, Poston GJ, Malik HZ. Hepatic steatosis, body mass index and long term outcome in patients undergoing hepatectomy for colorectal liver metastasis. Eur J Surg Oncol. (2010) 36:52–7. doi: 10.1016/J.EJSO.2009.09.004

25. Caan BJ, Meyerhardt JA, Kroenke CH, Alexeeff S, Xiao J, Weltzien E, et al. Explaining the obesity paradox: the association between body composition and colorectal cancer survival (C-SCANS study). Cancer Epidemiol Biomarkers Prev. (2017) 26:1008–15. doi: 10.1158/1055-9966.EPI-17-0200

26. Yang et al. 10.3389/fmed.2022.938718

27. Caan BJ, Meyerhardt JA, Kroenke CH, Alexeeff S, Xiao J, Weltzien E, et al. Explaining the obesity paradox: the association between body composition and colorectal cancer survival (C-SCANS study). Cancer Epidemiol Biomarkers Prev. (2017) 26:1008–15. doi: 10.1158/1055-9966.EPI-17-0200

28. Zhao J, Sawo P, Rensen SS, Roulart MMJ, Winstanley A, Vreuls CPH, et al. Impact of chemotherapy-associated liver injury on tumour regression grade and survival in patients with colorectal liver metastases. HPB (Oxford). (2018) 20:147–54. doi: 10.1111/HBP.2017.08.030

29. Behrns KE, Tsitotos GG, DeSouza NF, Krishna MK, Ludwig J, Nagorney DM. Hepatic steatosis as a potential risk factor for major hepatic resection. J Gastrointest Surg. (1998) 2:292–8. doi: 10.1016/S1091-255X(98)00025-5

30. Kooey DA, Fong Y, Suriawinata A, Gonen M, Allen PJ, Klimstra DS, et al. Impact of steatosis on perioperative outcome following hepatic resection. J Gastrointest Surg. (2003) 7:1034–44. doi: 10.1016/J.GASSUR.2003.09.012

31. Reddy SK, Marsh JH, Varley PB, Mock BK, Chopya KR, Geller DA, et al. Underlying steatohepatitis, but not simple hepatic steatosis, increases morbidity after liver resection: a case-control study. Hepatology. (2012) 56:2221–30. doi: 10.1002/HEP.25935

32. Reissfelder C, Brand K, Sobigalla J, Rahbari NN, Bork U, Schirmacher P, et al. Chemotherapy-associated liver injury and its influence on outcome after resection of colorectal liver metastases. Surgery. (2014) 155:245–54. doi: 10.1016/J.SURG.2013.07.022

33. Molla NW, Hassanain MM, Fidelz E, Boucher LM, MacKahli A, Althaman RM, et al. Effect of non-alcoholic liver disease on recurrence rate and liver regeneration after liver resection for colorectal liver metastases. Curr Oncol. (2017) 24:2333–43. doi: 10.3747/CO.24.3133

34. Kondo T, Okabashy K, Hasegawa H, Tsuruta M, Shigeta K, Kitagawa Y. The impact of hepatic fibrosis on the incidence of liver metastasis from colorectal cancer. Br J Cancer. (2016) 115:34–9. doi: 10.1038/BJC.2016.155

35. Narayan RB, Harris JW, Chou JF, Gonen M, Bao F, Shah J, et al. Prediction of recurrence patterns from hepatic parenchymal disease after resection of colorectal liver metastases. Ann Surg Oncol. (2020) 27:188–95. doi: 10.1245/ASO.2019.07.0794-3

36. Braumersreuther V, Viviani GL, Mach F, Montecucco F. Role of cytokines and chemokines in non-alcoholic liver disease. World J Gastroenterol. (2012) 18:727–35. doi: 10.3748/WJG.V18.I8.727

37. Marvin DL, Heijboer R, ten Dijke P, Ritsema C, TGF-β signaling in liver metastasis. Clin Transl Med. (2020) 10:160. doi: 10.1002/CTM.2.160

38. Li R, Wen A, Lin J. Pro-inflammatory cytokines in the formation of the pre-metastatic niche. Cancers (Basel). (2020) 12:1–16. doi: 10.3390/ Cancers12123752

39. Li Y, Su X, Robatj, N, Zhang Y, Brestoff JR, Shoghi KJ, et al. Hepatic lipids promote liver metastasis. JCI Insight. (2020) 5:136215. doi: 10.1172/JCI.INSIGHT.136215

40. Yang L, Li T, Shi H, Zhou Z, Huang Z, Lei X. The cellular and molecular components involved in pre-metastatic niche formation in colorectal cancer liver metastasis. Exp Rev Gastroen Hepatol. (2021) 15:389–99. doi: 10.1080/17474124.2021.1848549

41. Robinson SM, Wilson CH, Burt AD, Mamas DM, White SA. Chemotherapy-associated liver injury in patients with colorectal liver metastases: a systematic review and meta-analysis. Ann Surg Oncol. (2012) 19:4287–99. doi: 10.1245/ S10434-012-2438-8